Vaxart (NASDAQ:VXRT) Announces Earnings Results, Beats Estimates By $0.05 EPS

Vaxart (NASDAQ:VXRT) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.05, Zacks reports. Vaxart had a negative net margin of 431.61% and a negative return on equity of 110.46%.

Vaxart Stock Performance

Shares of VXRT traded down $0.02 during mid-day trading on Thursday, reaching $0.57. The company had a trading volume of 2,270,053 shares, compared to its average volume of 2,367,232. The company has a market capitalization of $129.14 million, a price-to-earnings ratio of -1.38 and a beta of 1.69. The firm has a 50-day moving average price of $0.66 and a 200 day moving average price of $0.71. Vaxart has a 52 week low of $0.45 and a 52 week high of $1.41.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.